Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.

Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK, Wang H, Ghimpeteanu G, Lee CJ

Diabetes care1 Dec 2023Cited by 50 (Europe PMC)

PMID37824793PMCIDPMC10698219DOI10.2337/dc23-1135PepBankPUB-37824793

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialOther
In adults with type 2 diabetes in SURPASS 1-4, higher tirzepatide doses were significantly associated with achieving a body weight reduction of 15% or more.
In plain wordsIn adults with type 2 diabetes, higher tirzepatide doses were linked to a greater chance of losing 15% or more of body weight.
Peptide
Tirzepatide
Outcome
IncreaseLikelihood of 15% or more weight reduction by tirzepatide dose
Study
n = 3,188
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
Factors significantly associated with achieving a BW reduction of ≥15% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, and lower HbA1c, fasting serum glucose, and non-HDL cholesterol at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479301
02HumanRandomized controlled trialOther
In adults with type 2 diabetes in SURPASS 1-4 on tirzepatide, female sex, White or Asian race, younger age, metformin background therapy and lower baseline HbA1c, glucose and non-HDL cholesterol were linked to achieving 15% or more weight reduction.
In plain wordsIn adults with type 2 diabetes on tirzepatide, traits such as female sex and younger age were linked to losing 15% or more weight.
Peptide
Tirzepatide
Outcome
MixedBaseline predictors of 15% or more weight reduction
Study
n = 3,188
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
Factors significantly associated with achieving a BW reduction of ≥15% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, and lower HbA1c, fasting serum glucose, and non-HDL cholesterol at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on tirzepatide, greater categories of body weight reduction were associated with greater HbA1c reductions.
In plain wordsIn adults with type 2 diabetes on tirzepatide, people who lost more weight also had larger HbA1c drops.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction by category of weight reduction
Study
n = 3,188
Comparator
Smaller weight reduction categories
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479303
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on tirzepatide, greater categories of body weight reduction were associated with greater triglyceride reductions.
In plain wordsIn adults with type 2 diabetes on tirzepatide, people who lost more weight also had larger triglyceride drops.
Peptide
Tirzepatide
Outcome
DecreaseTriglyceride reduction by category of weight reduction
Study
n = 3,188
Comparator
Smaller weight reduction categories
Outcome group
Lipids · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479304
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on tirzepatide, greater categories of body weight reduction were associated with greater ALT reductions.
In plain wordsIn adults with type 2 diabetes on tirzepatide, people who lost more weight also had larger drops in the liver enzyme ALT.
Peptide
Tirzepatide
Outcome
DecreaseALT reduction by category of weight reduction
Study
n = 3,188
Comparator
Smaller weight reduction categories
Outcome group
Liver fat and liver function · Liver
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479305
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on tirzepatide, greater categories of body weight reduction were associated with greater waist circumference reductions.
In plain wordsIn adults with type 2 diabetes on tirzepatide, people who lost more weight also lost more around the waist.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference reduction by category of weight reduction
Study
n = 3,188
Comparator
Smaller weight reduction categories
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479306
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on tirzepatide, greater categories of body weight reduction were associated with greater blood pressure reductions.
In plain wordsIn adults with type 2 diabetes on tirzepatide, people who lost more weight also had larger blood pressure drops.
Peptide
Tirzepatide
Outcome
DecreaseBlood pressure reduction by category of weight reduction
Study
n = 3,188
Comparator
Smaller weight reduction categories
Outcome group
Blood pressure · Cardiovascular
Studied dose
5, 10 or 15 mg · 40 or 42 weeksAs given in this study (human).
Source sentences
Summary
With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline characteristics and change from baseline to week 40/42 for efficacy parameters were described and analyzed in treatment-adherent participants (≥75% doses administered and on treatment at week 40/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).
Report a problemFND-3782479307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.